MannKind, the Westlake Village-based drug delivery platform, said Nov. 6 that revenue jumped 227 percent to $14.6 million for the third quarter as its loss narrowed to $10.4 million from $24 million a year earlier. The company said it earned $6.4 million in revenue for its core Afrezza insulin drug, including its first sales to…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
